These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34967559)

  • 21. Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
    Qiu M; Yang X; Hu J; Ding X; Jiang F; Yin R; Xu L
    PLoS One; 2013; 8(8):e72251. PubMed ID: 23977265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. XRCC3 Thr241Met and XPD Lys751Gln gene polymorphisms and risk of clear cell renal cell carcinoma.
    Loghin A; Bănescu C; Nechifor-Boila A; Chibelean C; Orsolya M; Nechifor-Boila A; Tripon F; Voidazan S; Borda A
    Cancer Biomark; 2016; 16(2):211-7. PubMed ID: 26682510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.
    Qin Q; Zhang C; Yang X; Zhu H; Yang B; Cai J; Cheng H; Ma J; Lu J; Zhan L; Liu J; Liu Z; Xu L; Sun X
    PLoS One; 2013; 8(11):e79864. PubMed ID: 24260311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in XPD and TP53 and mutation in human lung cancer.
    Mechanic LE; Marrogi AJ; Welsh JA; Bowman ED; Khan MA; Enewold L; Zheng YL; Chanock S; Shields PG; Harris CC
    Carcinogenesis; 2005 Mar; 26(3):597-604. PubMed ID: 15564288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
    Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population.
    Chen S; Tang D; Xue K; Xu L; Ma G; Hsu Y; Cho SS
    Carcinogenesis; 2002 Aug; 23(8):1321-5. PubMed ID: 12151350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.
    Wei SZ; Zhan P; Shi MQ; Shi Y; Qian Q; Yu LK; Song Y
    Med Oncol; 2011 Mar; 28(1):315-21. PubMed ID: 20143185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
    Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei DD; Groshen S; Lenz HJ
    Cancer Res; 2001 Dec; 61(24):8654-8. PubMed ID: 11751380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
    Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
    Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer.
    Brewster AM; Jorgensen TJ; Ruczinski I; Huang HY; Hoffman S; Thuita L; Newschaffer C; Lunn RM; Bell D; Helzlsouer KJ
    Breast Cancer Res Treat; 2006 Jan; 95(1):73-80. PubMed ID: 16319991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms of DNA repair genes XPD and XRCC1 and risk of cataract development.
    Unal M; Güven M; Batar B; Ozaydin A; Sarici A; Devranoğlu K
    Exp Eye Res; 2007 Sep; 85(3):328-34. PubMed ID: 17637462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms of the DNA repair genes XPD and XRCC1 and the risk of age-related macular degeneration.
    Görgün E; Güven M; Unal M; Batar B; Güven GS; Yenerel M; Tatlipinar S; Seven M; Yüksel A
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4732-7. PubMed ID: 20375340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
    Zhang L; Ma W; Li Y; Wu J; Shi GY
    Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India.
    Sreeja L; Syamala VS; Syamala V; Hariharan S; Raveendran PB; Vijayalekshmi RV; Madhavan J; Ankathil R
    J Cancer Res Clin Oncol; 2008 Jun; 134(6):645-52. PubMed ID: 17952468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of TP53 codon 72 and CDH1 genetic polymorphisms with colorectal cancer risk in Bangladeshi population.
    Rivu SF; Apu MNH; Shabnaz S; Nahid NA; Islam MR; Al-Mamun MMA; Nahar Z; Rabbi SNI; Ahmed MU; Islam MS; Hasnat A
    Cancer Epidemiol; 2017 Aug; 49():46-52. PubMed ID: 28554075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53 genetic polymorphisms and susceptibility to cervical cancer in Bangladeshi women: a case-control study.
    Apu MNH; Rashed AZM; Bashar T; Rahman MM; Mostaid MS
    Mol Biol Rep; 2020 Jun; 47(6):4357-4364. PubMed ID: 32424519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
    Avan A; Pacetti P; Reni M; Milella M; Vasile E; Mambrini A; Vaccaro V; Caponi S; Cereda S; Peters GJ; Cantore M; Giovannetti E
    Int J Cancer; 2013 Aug; 133(4):1016-22. PubMed ID: 23390054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.